secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2024-09-25T23:59:59+00:00
Accession:  0001493152-24-038112
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo Pharma reports Q4 FY2024 net loss $0.05/share; net loss down 48% YoY; awarded $1.9M NIDA grant
--------------------------------------------------------------------------------

- Q4 FY2024 net loss $1.3M ($0.05/sh) vs $2.5M ($0.10/sh) in Q4 FY2023.
- Full-year FY2024 net loss $8.2M ($0.32/sh) vs $11.7M ($0.47/sh) in FY2023.
- Cash and equivalents $3.1M at June 30, 2024; additional $10M available under loan agreement.
- Awarded up to $1.9M NIDA grant for IND-enabling activities for IV selonabant for pediatric cannabis poisoning.
- Expects to enroll first healthy volunteer in H1 2025 for IV formulation clinical study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315224038112/0001493152-24-038112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315224038112/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-038112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer